Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Larsen

Physician Assistant, Medical Ocean Springs, MS Physician Assistant

NPI 1144301458 CMS profile 10743314

3635 Bienville Blvd, Ocean Springs, MS 39564

Open in the dashboard

General payments

$10,626

527 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Larsen of Ocean Springs, MS is reported in the CMS Open Payments database as having received $10,626 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,261 119
2024 General $1,856 97
2023 General $2,111 113
2022 General $1,872 107
2021 General $1,526 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Larsen
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Ashley Larsen were reported at $3,261. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Ashley Larsen Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,526 $156 $41–$563 $132
2022 $1,872 $185 $55–$649 $149
2023 $2,111 $199 $58–$717 $160
2024 $1,856 $206 $62–$740 $164
2025 $3,261 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,567 138 payments
  2. Inspire Medical Systems, Inc. $1,123 11 payments
  3. AstraZeneca Pharmaceuticals LP $1,052 53 payments
  4. Actelion Pharmaceuticals US, Inc. $970 35 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $883 48 payments
  6. United Therapeutics Corporation $651 30 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $489 23 payments
  8. Genzyme Corporation $414 21 payments
  9. Merck Sharp & Dohme Corporation $333 16 payments
  10. Mylan Specialty L.P. $272 16 payments
  11. Other $2,871 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,833 522 payments
  2. Travel and Lodging $685 3 payments
  3. Education $108 2 payments
Products named General payments · program years 2021–2025
  1. INSPIRE $1,123 11 payments
  2. UPTRAVI $970 35 payments
  3. OFEV $928 55 payments
  4. TRELEGY ELLIPTA $839 84 payments
  5. NUCALA $698 49 payments
  6. GLASSIA $489 23 payments
  7. TEZSPIRE $427 18 payments
  8. FASENRA $416 22 payments
  9. DUPIXENT $414 21 payments
  10. YUPELRI $393 22 payments
  11. Other $5,285 248 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

789

Median for Physician Assistant: 241

Drug cost

$242,936

Median for Physician Assistant: $4,110

Branded share of claims

63.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 147 $121,584
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 52 $36,912
Breo Ellipta Fluticasone/Vilanterol Brand 69 $30,889
Spiriva Respimat Tiotropium Bromide Brand 30 $24,179
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 14 $7,312
Symbicort Budesonide/Formoterol Fumarate Brand 21 $6,193
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 12 $5,746
Albuterol Sulfate Hfa Albuterol Sulfate Brand 139 $4,528
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 16 $2,228
Montelukast Sodium Generic 78 $1,150

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$24,957

Medicare's payments for the services billed

Medicare patients

412

Average age 73

Services billed

509

212 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 42%
Ischemic heart disease 36%
Chronic kidney disease 34%
COPD 32%
Depression 27%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $187
$187 — —
DUPIXENT
  • GENZYME CORPORATION $118
  • Regeneron Healthcare Solutions, Inc. $33
$152 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $147
$147 — —
TYVASO
  • United Therapeutics Corporation $134
$134 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $120
$120 147 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record